ACTA1 and colorectal carcinoma: Our results demonstrate that SB significantly reduces the expression of key CAFs markers, including α-SMA and POSTN, at both protein and mRNA levels, indicating its potential to suppress CAFs activity as a therapeutic strategy for CRC.